Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis and HIV Infection.

Buitrago1, Friedland

  • 1AIDS Program, Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT 06520, USA.

Current Infectious Disease Reports
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subharmonic autoresonance

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same author

Second harmonic autoresonant control of the l=1 diocotron mode in pure-electron plasmas

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same author

Mikheyev-smirnov-wolfenstein effects in vacuum oscillations

Physical review letters·2000
Same author

New Concept for the Reduction of Impurity Scattering in Remotely Doped GaAs Quantum Wells.

Physical review letters·1996
Same author

Magnetotransport phenomena in periodically delta -doped structures.

Physical review. B, Condensed matter·1995
Same author

Quality-of-Life Issues Associated With the Treatment of Prostate Cancer.

Cancer control : journal of the Moffitt Cancer Center·1995

New guidelines suggest shorter, intermittent tuberculosis treatment and prophylaxis for individuals with HIV. Substituting rifabutin for rifampin offers similar efficacy with fewer antiretroviral drug interactions.

Area of Science:

  • Infectious Diseases
  • Public Health
  • HIV/AIDS Research

Background:

  • Tuberculosis (TB) remains a significant opportunistic infection in individuals with Human Immunodeficiency Virus (HIV).
  • Optimizing treatment and prophylaxis regimens for dual TB/HIV infection is crucial for patient outcomes and public health.
  • Previous treatment protocols often involved longer durations and potential drug-drug interactions.

Purpose of the Study:

  • To review and summarize updated recommendations for TB treatment and prophylaxis in HIV-infected individuals.
  • To highlight advancements in regimen duration, frequency, and drug selection.
  • To assess the comparative efficacy and safety of alternative drug choices.

Main Methods:

  • Review of large-scale studies and expert consensus panel findings.

Related Experiment Videos

  • Analysis of data on shorter and intermittent antituberculous drug regimens.
  • Evaluation of studies comparing rifabutin and rifampin in TB/HIV co-infected patients.

    • Main Results:

    • Shorter and intermittent antituberculous regimens are now considered adequate for treating TB in HIV-infected individuals.
    • Rifabutin demonstrates equivalent efficacy to rifampin for TB treatment and prophylaxis in this population.
    • Rifabutin offers a significant advantage due to fewer drug interactions with antiretroviral medications.

    Conclusions:

    • Updated recommendations support shorter, intermittent TB treatment and prophylaxis regimens for HIV-infected individuals.
    • Rifabutin is a viable alternative to rifampin, offering comparable efficacy and an improved safety profile regarding antiretroviral interactions.
    • These changes aim to improve adherence, reduce pill burden, and minimize adverse drug events in co-infected patients.